KIORA PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
KIORA PHARMACEUTICALS, INC. (KPRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $2.35 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.98.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.83, a 403.95% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $0.76, a 88.24% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $2.90, a 33.33% decline from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $4.35, a 56.50% decline from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $10.00, a 17.79% increase from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $8.49, a 94.83% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.35 10-Q · filed 2026-08-07 | ||||||
| 2026-03-31 | $1.98 10-Q · filed 2026-05-08 | ||||||
| 2025-12-31 | $2.90 10-K · filed 2026-03-25 | ||||||
| 2025-09-30 | $2.93 10-Q · filed 2025-11-07 | ||||||
| 2025-06-30 | $2.93 10-Q · filed 2025-08-08 | ||||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | ||||||
| 2024-12-31 | $4.35 10-K · filed 2026-03-25 | ||||||
| 2024-09-30 | $4.35 10-Q · filed 2024-11-08 | ||||||
| 2023-12-31 | $10.00 10-K · filed 2025-03-25 | $1.11 10-K · filed 2024-03-25 | |||||
| 2023-09-30 | $1.11 10-Q · filed 2023-11-09 | ||||||
| 2023-06-30 | $3.62 10-Q · filed 2023-08-08 | ||||||
| 2023-03-31 | $3.83 10-Q · filed 2023-05-09 | ||||||
| 2022-12-31 | $8.49 10-K · filed 2024-03-25 | ||||||
| 2022-09-30 | $30.40 10-Q · filed 2022-11-09 | ||||||
| 2022-06-30 | $0.76 10-Q · filed 2022-08-12 | ||||||
| 2022-03-31 | $0.76 10-Q · filed 2022-07-08 | ||||||
| 2021-12-31 | $164.30 10-K · filed 2023-03-23 | $4.11 10-K · filed 2022-04-15 | |||||
| 2021-09-30 | $191.99 10-Q · filed 2022-11-09 | $4.80 10-Q · filed 2021-11-15 | |||||
| 2021-06-30 | $6.19 10-Q · filed 2022-08-12 | ||||||
| 2021-03-31 | $6.46 10-Q · filed 2021-05-12 | ||||||
| 2020-12-31 | $6.31 10-K/A · filed 2022-07-07 | ||||||
| 2020-09-30 | $6.31 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | $6.31 10-Q · filed 2021-08-12 | $6.31 10-Q · filed 2020-08-06 | |||||
| 2020-03-31 | $6.55 10-Q · filed 2021-05-12 | ||||||
| 2019-12-31 | $7.20 10-K · filed 2021-03-25 | ||||||
| 2019-09-30 | $7.20 10-Q · filed 2020-11-09 | ||||||
| 2019-06-30 | $7.20 10-Q · filed 2020-08-06 | $0.48 10-Q · filed 2019-08-08 | |||||
| 2019-03-31 | $7.20 10-Q · filed 2020-05-06 | ||||||
| 2018-12-31 | $8.55 10-K · filed 2020-03-04 | ||||||
| 2018-09-30 | $8.55 10-Q · filed 2019-11-07 | ||||||
| 2018-06-30 | $0.57 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |